GSK Flonase suit
This article was originally published in The Tan Sheet
GlaxoSmithKline has dropped its lawsuit disputing FDA's approval of generic Flonase (fluticasone propionate). GSK decided not to appeal the March 6 ruling of Baltimore federal court Judge Andre Davis that denied the firm's request for a preliminary injunction on the sale of the generic nasal spray. FDA's approval of the generic nasal spray Feb. 22 prompted GSK to file suit; the court granted the firm a temporary restraining order suspending FDA approval of the drug until March 6 (1"The Tan Sheet" Feb. 27, 2006, p. 4). GSK discontinued plans for an Rx-to-OTC switch of Flonase in favor of pursuing legal action against the sale of generics, and now says it has no plans to resume a switch program...
You may also be interested in...
GlaxoSmithKline has shelved an OTC switch of Flonase nasal steroid as a competitive strategy in favor of litigation to block generics
Not all technology platforms provide the expected benefit of filling in CMC review gaps and speeding coronavirus vaccine approvals.
A long-term, patient-centric group of investors is backing SparingVision's bid to develop a gene therapy treatment for retinitis pigmentosa that could be effective regardless of mutation.